An efficacy trial of the malaria vaccine SPf66 in Gambian infants-second year of follow-up

By Bojang K.A.   Obaro S.K.   D'Alessandro U.   Bennett S.   Langerock P.   Targett G.A.T.   Greenwood B.M.  

Vaccine, Vol. 16, Iss. 1, 1998-01 ,pp. : 62-67

Elsevier

Access to resources Recommend Favorite

The effect of temperature on the stability of the synthetic SPf(66)n malaria vaccine

By Lopez M.C.   Thomas M.C.   Olivares M.   Alonso P.   Alonso C.  

Vaccine, Vol. 13, Iss. 13, 1995-01 ,pp. : 1180-1182

Elsevier

Access to resources Recommend Favorite

Safety, tolerability and immunogenicity of new formulations of the Plasmodium falciparum malaria peptide vaccine SPf66 combined with the immunological adjuvant QS-21

By Kashala O.   Amador R.   Valero M.V.   Moreno A.   Barbosa A.   Nickel B.   Daubenberger C.A.   Guzman F.   Pluschke G.   Patarroyo M.E.  

Vaccine, Vol. 20, Iss. 17, 2002-05 ,pp. : 2263-2277

Elsevier

Access to resources Recommend Favorite

Biodegradable PLGA microspheres as a delivery system for malaria synthetic peptide SPf66

By Rosas J.E.   Hernandez R.M.   Gascon A.R.   Igartua M.   Guzman F.   Patarroyo M.E.   Pedraz J.L.  

Vaccine, Vol. 19, Iss. 31, 2001-08 ,pp. : 4445-4451

Elsevier

Access to resources Recommend Favorite

Field trial of inactivated oral cholera vaccines in Bangladesh: results from 5 years of follow-up

By van Loon F.P.L.   Clemens J.D.   Chakraborty J.   Rao M.R.   Kay B.A.   Sack D.A.   Yunus M.   Ali M.   Svennerholm A.-M.   Holmgren J.  

Vaccine, Vol. 14, Iss. 2, 1996-02 ,pp. : 162-166

Elsevier

Access to resources Recommend Favorite